⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRM News
Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Primary Biliary Cholangitis Pipeline Report 2026: 25+ Therapies from 20+ Companies, Led by Saroglitazar and CNP-104
globenewswire.com
MIRM
Form 8-K
sec.gov
MIRM
Radiation Detection, Monitoring & Safety Market Forecasts Growth from $3.80B (2026) to $5.68B by 2031, Profiling Fortive, Thermo Fisher & Mirion Technologies
globenewswire.com
FTV
TMO
MIRM
Mirum Pharmaceuticals annonce que le critère d’évaluation principal a été atteint dans l’étude de phase III AZURE-1 portant sur le brelovitug dans le traitement de l’infection chronique par le virus de l’hépatite D (VHD)
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP)
businesswire.com
MIRM
INCY
Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva
businesswire.com
MIRM
INCY
Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva
businesswire.com
MIRM
INCY